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Adiposity in childhood brain
tumors: A report from the
Canadian Study of Determinants of
Endometabolic Health in Children
(CanDECIDE Study)
Kuan-Wen Wang1,2,3, Russell J. de Souza1,4, Adam Fleming1,2,5, Sheila K. Singh6,7,
Donna L. Johnston8, Shayna M. Zelcer9, Shahrad Rod Rassekh10, Sarah Burrow11,
Katrin Scheinemann2,12, Lehana Thabane1,4,13,14,15 & M. Constantine Samaan1,2,3,4
Children with brain tumors (CBT) are at high risk of cardiovascular diseases and type 2 diabetes
compared to the general population. Recently, adiposity has been reported to be more informative for
cardiometabolic risk stratification than body mass index (BMI) in the general population. The goal of
this study is to describe the adiposity phenotype in CBT, and to establish adiposity determinants. We
recruited CBT (n = 56) and non-cancer controls (n = 106). Percent body fat (%FM), waist-to-hip ratio
(WHR) and waist-to-height ratio (WHtR) were measured to determine total and central adiposity,
respectively. Regression analyses were used to evaluate adiposity determinants. CBT had higher total
and central adiposity compared to non-cancer controls despite having similar BMI measurements.
Those with tumors at the supratentorial region had increased total and central adiposity, while those
who received radiotherapy had increased total adiposity. In conclusion, CBT have increased total and
central adiposity in the presence of similar BMI levels when compared to non-cancer controls. Adiposity,
especially central adiposity, is a potential cardiometabolic risk factor present relatively early in life
in CBT. Defining interventions to target adiposity may improve long-term outcomes by preventing
cardiometabolic disorders in CBT.
Brain tumors are the most common pediatric solid tumors1. Groundbreaking discoveries in tumor biology and
advances in diagnosis and therapy have significantly improved the survival of many of these children2. As the
number of survivors has risen, it has become evident that this group is at risk of developing chronic morbidities3,4
and premature mortality5,6.
Recent evidence suggests that adult survivors of childhood brain tumors are at risk of cardiovascular diseases, including stroke, cardiac events, and type 2 diabetes7–10. As obesity is an independent risk factor for
1

Medical Sciences Program, McMaster University, Hamilton, Ontario, Canada. 2Department of Pediatrics, McMaster
University, Hamilton, Ontario, Canada. 3Division of Pediatric Endocrinology, McMaster Children’s Hospital, Hamilton,
Ontario, Canada. 4Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton,
Ontario, Canada. 5Division of Pediatric Hematology/Oncology, McMaster Children’s Hospital, Hamilton, Ontario,
Canada. 6Division of Neurosurgery, Department of Surgery, McMaster Children’s Hospital, Hamilton, Ontario,
Canada. 7McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada.
8
Division of Pediatric Hematology/Oncology, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
9
Pediatric Hematology Oncology, London Health Sciences Center, London, Ontario, Canada. 10Division of Pediatric
Hematology/Oncology/BMT, Department of Pediatrics, British Columbia Children’s Hospital, Vancouver, BC, Canada.
11
Division of Orthopedic Surgery, Department of Surgery, McMaster University Medical Centre, Hamilton, Ontario,
Canada. 12Division of Hematology/Oncology, University Children’s Hospital, Basel, Switzerland. 13Department of
Anesthesia, McMaster University, Hamilton, Ontario, Canada. 14Centre for Evaluation of Medicines, St. Joseph’s
Health Care, Hamilton, ON, Canada. 15Biostatistics Unit, St. Joseph’s Healthcare-Hamilton, Ontario, Canada.
Correspondence and requests for materials should be addressed to M.C.S. (email: samaanc@mcmaster.ca)
SCIENTIfIC REporTS | 7:45078 | DOI: 10.1038/srep45078

1

www.nature.com/scientificreports/
Non-cancer controls (n = 106)
Variables
Age (years)

CBT (n = 56)

Total Mean (SD) Male Mean (SD) Female Mean (SD) Total Mean (SD) Male Mean (SD) Female Mean (SD)
14.00 (2.80)

14.00 (2.60)

14.00 (3.00)

14.70 (7.10)

14.80 (5.50)

14.50 (9.00)

Sex, No. (%)
Female

51.00 (48.10)

—

—

23.00 (41.10)

—

—

Male

55.00 (51.90)

—

—

33.00 (58.90)

—

—

Height (cm)

161.70 (15.30)

166.00 (16.80)

157.20 (11.90)

150.60 (25.20)

155.90 (26.10)

143.00 (22.30)

Weight (kg)

59.00 (20.80)

64.30 (25.00)

53.50 (13.30)

52.40 (24.10)

55.20 (23.00)

48.50 (25.50)

BMI (kg/m2)

22.10 (5.60)

22.80 (6.60)

21.40 (4.10)

21.60 (5.50)

21.40 (4.40)

21.80 (6.80)

BMI z-score

0.49 (1.16)

0.58 (1.27)

0.41 (1.02)

0.41 (1.15)

0.32 (1.26)

0.55 (0.96)
14.00 (60.90)

BMI category, No. (%)
BMI%ile <  85

69.00 (65.10)

34.00 (61.80)

35.00 (68.60)

36.00 (64.30)

22.00 (66.70)

BMI%ile ≥  85

37.00 (34.90)

21.00 (38.10)

16.00 (31.40)

20.00 (35.70)

11.00 (33.30)

9.00 (39.10)

22.20 (9.00)

19.10 (9.00)

25.60 (7.80)

25.80 (9.60)

23.00 (9.40)

29.90 (8.60)

%FM
WHR

0.82 (0.09)

0.84 (0.08)

0.80 (0.10)

0.87 (0.07)

0.86 (0.07)

0.88 (0.08)

WHtR

0.45 (0.08)

0.45 (0.09)

0.44 (0.07)

0.47 (0.06)

0.47 (0.06)

0.48 (0.07)

Sys BP (mmHg)

107.20 (10.60)

110.40 (10.60)

103.70 (9.60)

104.00 (11.50)

104.10 (11.60)

103.90 (11.80)

Dia BP (mmHg)

67.60 (9.60)

67.10 (10.00)

68.10 (9.10)

66.30 (8.50)

66.20 (8.50)

66.40 (8.80)

97.00 (91.50)

48.00 (87.30)

49.00 (96.10)

43.00 (76.80)

25.00 (75.80)

18.00 (78.30)

9.00 (8.50)

7.00 (12.70)

2.00 (3.90)

13.00 (23.20)

8.00 (24.20)

5.00 (21.70)

Screen time (hours/day)

4.30 (2.60)

4.80 (2.70)

3.80 (2.50)

4.50 (2.70)

4.80 (2.60)

3.90 (2.70)

Sleep duration (hours/day)

9.50 (1.40)

9.70 (1.70)

9.40 (1.10)

9.60 (1.20)

9.40 (1.20)

9.70 (1.10)

Physical activity, No. (%)
Active
Inactive

Table 1. Characteristics of study population. Abbreviations: SD, Standard Deviation; BMI, Body Mass Index;
%tile, percentile; %FM, fat mass percentage; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; Sys BP,
systolic blood pressure; Dia BP, diastolic blood pressure; mmHg, millimeter Mercury.

cardiometabolic disorders in the general population, it may provide an explanation of the added cardiometabolic
risk in survivors11. However, when obesity rates are measured by using Body Mass Index (BMI), children with
brain tumors (CBT) are reported to have BMI levels that are either close to or slightly higher than rates in the
general population, which does not seem to explain this increased cardiometabolic risk in survivors12,13.
While BMI is the most widely used clinical measure of obesity, it does not distinguish the relative contribution
of fat, muscle, or bone to body mass, which are considerably variable in growing children14.
On the other hand, adiposity may be a better measurement to determine cardiometabolic risk in CBT.
Adiposity is defined as the presence of fat in and outside the adipose tissue, including muscle and hepatic fat
depots. The adipose depot is composed of a subcutaneous compartment, which is considered protective against
cardiometabolic risk15,16. On the other hand, the visceral adipose compartment secretes inflammatory cytokines
which can lead to insulin resistance, and is linked to adverse cardiometabolic outcomes17.
Measures of total adiposity (fat mass percentage; %FM) and central adiposity, including waist-to-hip ratio
(WHR) and waist-to-height ratio (WHtR), have been shown to be more robust predictors of cardiometabolic
health and risk compared to BMI18–24, with WHtR emerging as a strong indicator of intra-abdominal fat25.
However, adiposity is not routinely measured in children, including pediatric cancer patients. While brain
tumors are a heterogeneous group, a common tumor classically reported to be associated with obesity is craniopharyngioma26. There have been very few reports on the evaluation of obesity in other brain tumor subtypes and
beyond hypothalamic obesity27,28. As BMI-based obesity rates are similar between CBT and controls yet CBT have
high risk of cardiometabolic disorders, we hypothesized that CBT, excluding craniopharyngioma, have higher
adiposity when compared to non-cancer controls. This excess adiposity may contribute to adverse cardiometabolic outcomes and premature mortality. A secondary aim of this study was to investigate the determinants of
adiposity in CBT.

Results

We included 56 CBT (n = 23 female) and 106 non-cancer controls (n = 51 female) in this study. The characteristics of the study population are reported in Table 1.
The two groups were similar in terms of age (CBT: 5.20–42.70 years; controls: 5.40–18.80 years; p-value 0.59)
and sex distribution (p-value 0.39). The CBT group had more participants in prepubertal stage (n =  19, 33.90%)
versus controls (n = 16, 15.10%). Age of diagnosis of brain tumor was 9.10 ± 4.90 years, and average time since
diagnosis was 5.60 ±  5.10 years.
As reported previously29, CBT were shorter (150.60 ± 25.20 versus 161.70 ± 15.30 cm, p-value =  0.002) and
weighed less (52.40 ± 24.10 versus 59.00 ± 20.80 kg, p-value = 0.02) than the control group.
The %FM correlated with central adiposity (Spearman’s rho test WHR 0.31, p-value < 0.001; WHtR 0.73,
p-value < 0.001). Central adiposity measures were highly correlated with each other as well (Spearman’s rho test
0.67, p-value <  0.001).
SCIENTIfIC REporTS | 7:45078 | DOI: 10.1038/srep45078
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Variables

No. (%)
Brain tumor type

CNS germ cell tumors

5 (8.90)

PNET/Medulloblastoma

11 (19.60)

Ependymoma

2 (3.60)

Subependymal giant cell astrocytoma

3 (5.40)

Meningioma

1 (1.80)

NF-1, low grade glioma

10 (17.85)

Non-NF-1, low grade glioma

24 (42.85)

Brain tumor location
Supratentorial

26 (46.40)

Infratentorial

30 (53.60)
Brain tumor treatments

Surgery

41 (73.20)

Radiotherapy

22 (39.30)

Chemotherapy

27 (48.20)

No treatment

8 (14.30)

Steroids

27 (48.20)

Table 2. Brain tumor type, location, and treatments. Abbreviations: PNET, Primitive Neuroectodermal
Tumor; NF-1, Neurofibromatosis Type 1.

The total screen time and sleep duration were similar between the two groups (Table 1). The most common tumor subtypes in participants included gliomas (n = 34, 60.70%) and Primitive Neuroectodermal tumors (PNET)/medulloblastoma (n = 11, 19.60%) (Table 2). The tumors were distributed between supratentorial
(n = 26, 46.40%) and infratentorial regions (n = 30, 53.60%) (Table 2), with only 7 patients (12.50%) having
tumors involving the hypothalamus. The therapeutic modalities were used in the management of brain tumors
are shown in Table 2. Surgery alone was the most common treatment modality (n = 18, 32.10%), followed by a
combination of surgery, chemotherapy and radiotherapy (n = 15, 26.80%). Chemotherapy alone was noted in five
cases (8.90%), and radiotherapy alone was implemented in one patient (1.80%). Four patients (7.10%) received
surgery and chemotherapy, and four (7.10%) received surgery and radiotherapy; one received radiotherapy and
chemotherapy (1.80%).
In the 22 participants who received radiotherapy, the radiotherapy dosage was 47.10 ± 12.40 Gy. Sixteen participants received craniospinal irradiation (72.70%), and six received cranial irradiation (27.30%). Eight patients
were being managed with watch-and-wait strategy (14.30%).
Post-therapy endocrinopathies were observed in 14 (26.80%) CBT participants. Among this group, a single
diagnosis was made in seven patients including hypothyroidism (n = 3, 21.40%), growth hormone deficiency
(n = 2, 14.30%), hypogonadism (n = 1, 7.10%), and precocious puberty (n = 1, 7.10%). The other seven patients
had multiple hormonal deficiencies including hypothyroidism (n = 5, 35.70%), growth hormone deficiency
(n = 6, 42.90%), hypogonadism (n = 4, 28.60%), adrenocorticotropic hormone deficiency (n =  4, 28.60%),
diabetes insipidus (n = 3, 21.40%), and precocious puberty (n = 1, 7.10%). All endocrinopathies were treated
appropriately.

Adiposity patterns in CBT and controls.

To determine if CBT have enhanced adiposity compared to
non-cancer controls, we used logistic regression analysis.
CBT had higher total adiposity compared to controls (%FM 25.50 ± 9.60% versus 22.40 ±  9.30%; β  =  1.51,
95% CI = 1.08, 2.10, p-value = 0.016). CBT also had higher central adiposity compared to controls including
higher WHR (0.87 ± 0.07 versus 0.82 ±  0.09; β  = 7.53, 95% CI = 2.30, 24.64, p-value = 0.001) and a trend of
higher WHtR (0.47 ± 0.06 versus 0.45 ±  0.08; β  = 0.34, 95% CI = 0.12, 1.02, p-value =  0.053).
Importantly, there were no differences in BMI and overweight/obesity rates between CBT and non-cancer
controls (Table 1). BMI correlated with total adiposity (%FM) in CBT and controls (Spearman’s rho test CBT
0.50, p-value < 0.001; controls 0.76, p-value < 0.001). BMI also correlated with WHR in controls but not in CBT
(Spearman’s rho test CBT 0.41, p-value 0.12; controls 0.17, p-value 0.038). Furthermore, BMI correlated with
WHtR in CBT and controls (Spearman’s rho test CBT 0.51, p-value < 0.001; controls 0.73, p-value <  0.001). These
results demonstrate that CBT have higher total and central adiposity compared to non-cancer controls, in the
presence of similar obesity rates based on BMI measurements.

Determinants of adiposity in survivors and controls. To define the determinants of adiposity, we conducted separate exploratory subgroup analyses using multivariate linear regression for CBT and controls (Table 3
for CBT; Supplementary Table S1 for controls). Dietary data are included in Table 4.
Females in the control group had higher total adiposity, while males had increased WHR, and puberty was
associated with all measures of adiposity. These trends were not noted in CBT.
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%FM
Variables

WHR

WHtR

β (SE)

P-value

β (SE)

P-value

β (SE)

Age

−0.12 (0.10)

0.23

−0.28 (0.03)

0.29

−0.02 (0.03)

0.50

Sex

0.55 (0.52)

0.30

−0.13 (0.14)

0.36

−0.13 (0.18)

0.46

Puberty

P-value

1.11 (0.99)

0.28

0.28 (0.26)

0.29

0.35 (0.34)

0.32

Brain tumor type

−0.33 (0.44)

0.46

−0.06 (0.11)

0.58

0.08 (0.15)

0.61

Brain tumor location

−1.83 (0.80)

0.028

−0.37 (0.21)

0.08

−0.53 (0.27)

0.06

0.91 (0.81)

0.27

0.08 (0.21)

0.69

0.20 (0.28)

0.47

Radiotherapy

1.65 (0.79)

0.046

0.08 (0.21)

0.69

0.22 (0.27)

0.43

Chemotherapy

−0.86 (0.74)

0.25

0.06 (0.19)

0.77

−0.02 (0.25)

0.93

Surgery

Steroids

0.68 (0.62)

0.28

0.04 (0.16)

0.81

0.21 (0.21)

0.32

Prudent diet

0.13 (0.33)

0.68

0.06 (0.08)

0.44

0.06 (0.11)

0.62

Western diet
High-protein diet
Refined carbohydrate
diet
Physical inactivity

0.15 (0.33)

0.64

0.04 (0.09)

0.64

0.17 (0.11)

0.13

−0.19 (0.27)

0.48

−0.02 (0.07)

0.76

−0.09 (0.09)

0.33

0.38 (0.29)

0.20

0.06 (0.08)

0.43

0.07 (0.10)

0.45

−0.89 (0.57)

0.12

−0.12 (0.15)

0.42

−0.26 (0.19)

0.19

Screen time

1.08 (1.33)

0.42

0.14 (0.34)

0.68

0.42 (0.46)

0.37

Sleep duration

6.41 (7.24)

0.38

1.77 (1.87)

0.35

1.44 (2.49)

0.57

Table 3. The determinants of adiposity in participants with brain tumors. Abbreviations: %FM, Percent Fat
Mass; WHR, Waist-to-Hip Ratio; WHtR, Waist-to-Height Ratio; SE, standard error.

Factor loadings
Items

Prudent Western High-protein Refined carbohydrate

Fruits

0.73

—

—

—

Vegetables

0.70

—

—

—

Water

0.57

—

—

—

Crackers

0.52

—

—

—

Grain

0.49

—

—

—

Juice

—

−0.18

—

—

Fried Foods

—

0.68

—

—

Desserts

—

0.61

—

—

Baked Goods

—

0.56

—

—

Chips

—

0.53

—

—

Snacks

—

0.53

—

—

Candies

—

0.51

—

—

Poultry

−0.31

—

0.67

—

Red Meat

—

—

0.63

—

Eggs

—

—

0.57

—

−0.39

—

0.40

—

0.30

−0.31

0.38

—

White Bread

—

0.30

—

0.71

Dark Bread

Soft Drinks
Peanut/other nuts

0.35

—

0.34

−0.67

Gelatin

—

—

—

0.66

Fish

—

—

—

0.37

Dairy

—

—

—

0.35

15.7

10.1

8.4

7.1

Total variance explained (%)

Table 4. Factor loading matrix for dietary patterns in participants. Absolute values < 0.30 were not listed in
the table, except for juice whose highest value of factor loading is shown. Absolute values > 0.50 were bolded to
emphasize strength of association and determination of dietary patterns.

CBT with Supratentorial tumors had increased total adiposity (β −1.83, SE 0.80, p-value 0.028), with trended
association with central adiposity (WHR β −0.37, SE 0.21, p-value 0.08; WHtR β −0.53, SE 0.27, p-value 0.06)
(Table 3).
CBT who received radiotherapy had higher %FM (β  = 1.65, SE 0.79, p-value = 0.046). However, radiotherapy
type (craniospinal versus cranial irradiation) and radiation dose did not correlate with %FM (Spearman’s rho test
radiotherapy type r 0.13, p-value 0.57; Dose r 0.24, p-value 0.36), WHR (Spearman’s rho test radiotherapy type
SCIENTIfIC REporTS | 7:45078 | DOI: 10.1038/srep45078
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r 0.18, p-value 0.43; Dose r 0.33, p-value 0.17), or WHtR (Spearman’s rho test radiotherapy type r 0.10, p-value
0.67; Dose r 0.24, p-value 0.3)’.
While 27 (48.2%) CBT were treated with corticosteroids, there was no association between steroid use and
%FM (β  = 0.68, SE 0.62, p-value = 0.28), WHR (β  = 0.04, SE 0.19, p-value = 0.81), or WHtR (β  = 0.21, SE 0.21,
p-value =  0.32) (Table 3).
When examining the contribution of lifestyle factors (diet, physical activity, screen time, sleep duration) to
adiposity in controls, physical inactivity trended with WHR, while screen time was associated with WHtR. Diet
and sleep duration were not associated with adiposity measures. None of the lifestyle factors were associated
with total or central adiposity measures in CBT (Table 3 for CBT; Supplementary Table S1 for controls; Diet data
Table 4).

Discussion

The improved survival rates of children with brain tumors have been hindered by premature mortality and the
development of morbidities. Of particular importance, recent evidence confirms that survivors are at risk of type
2 diabetes and cardiovascular diseases7–10. In this study, we demonstrate that adiposity, one of the most important
determinants of cardiometabolic risk, is enhanced in CBT when compared to non-cancer controls.
Importantly, the adipose phenotype noted in CBT is evident with equivalent overweight/obesity rates to controls based on BMI measurements.
It has been reported that BMI can underestimate the prevalence of obesity in childhood cancer survivors,
including survivors of brain tumors18. Until further knowledge is generated of the potential role of early excess
adiposity in programming future cardiometabolic risk in CBT, there is a need to measure both BMI and adipose
depots, and to continue to attempt to define their determinants. Our data are consistent with studies that used
dual X-ray absorptiometry (DXA) scans30, and reported the presence of higher total adiposity in cancer survivors who were treated with cranial irradiation30. The first study identified impaired mobility as an association of
adiposity; the second study recruited patients with different cancers including brain tumors, and used siblings
as a control group. The latter study identified male sex and screen time as risk factors of adiposity30. Our study
population included CBT exclusively, with non-cancer controls as a comparison group. This may explain why the
previously identified risk factors were not associated with adiposity in our study.
An important contribution of our study is that it provides evidence for the use of clinically feasible measures
to determine adiposity in CBT. This has important implications for settings where access to DXA is not practical
or possible, allowing clinicians to estimate the adiposity patterns in their survivor populations.
Our data also demonstrate that tumor location and radiotherapy have important associations with adiposity.
Supratentorial tumors were associated with enhanced total and central adiposity, while radiotherapy was associated with excess total adiposity.
While tumors and their treatment can lead to anatomical or functional hypothalamic-pituitary damage with
pituitary hormonal deficiencies31, disruption of hypothalamic satiety signaling and reduced basal metabolic rate
that can drive obesity26, these factors may also contribute to excess adiposity.
Our results did not corroborate previous evidence of the association of higher doses of radiotherapy with
obesity in childhood cancers, including brain tumors32,33. While these studies used BMI to measure obesity, our
results suggest that adiposity may be associated with radiotherapy regardless of dosage. Clarifying the effect of
radiotherapy type, dosing and fractionation on adiposity is an important question to address in CBT.
Endocrinopathies have been reported to increase the risk of higher BMI, but their effect on adiposity patterns in CBT early on requires further study, as these effects may become more apparent as CBT age. Given that
radiation dosage is associated with hormonal abnormalities in cancer survivors, the effect of radiation dosage on
adiposity may have been masked in our population who were treated for existing endocrinopathies34.
It has been reported that certain tumors including craniopharyngiomas, pilocytic astrocytomas, and medulloblastomas are associated with elevated BMI33. We purposefully excluded craniopharyngiomas, to determine the
contribution of other tumors to the adipose phenotype in CBT. A larger sample size is needed to clarify whether
adiposity is driven by specific tumor types.
Several lifestyle factors are associated with obesity in the general pediatric population, Including excess caloric
intake from sugar-sweetened beverages, prolonged screen time, and short sleep duration. Physical inactivity has
been a controversial determinant of obesity in children35–39.
While biological (sex), hormonal (puberty) and lifestyle factors were associated with adiposity in controls,
none emerged as an explanation of the enhanced adiposity profile in CBT, which was associated with tumor
location and radiotherapy.
The lack of association of diet with adiposity in our study is consistent with a study in craniopharyngioma
patients, which revealed that physical inactivity, and not nutritional factors, were associated with higher adiposity40. As our study is cross-sectional, one caveat is that the dietary patterns may have changed from the time of
diagnosis onwards. Longitudinal studies are needed to clarify the link between diet and adiposity in CBT.
The association of physical inactivity with childhood obesity and its use as a treatment for obesity has yielded
inconsistent results41–44. In CBT, physical inactivity can be driven by treatment-related pulmonary and cardiac
dysfunction45,46, reduced muscle strength and fitness47, fatigue, sleep disturbance48, mental health issues, visual
impairment, imbalance and pain49,50. Further studies on the association of physical inactivity with adiposity, and
fat mass modification by targeted interventions in CBT are needed.
Our data suggest that within few years from having a brain tumor, CBT are following the secular lifestyle
trends noted in the general population. However, the effect of adopting these trends on adiposity and cardiometabolic risk in CBT can be disproportionate, due to the added burden of the tumor and its treatment. Multipronged,
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personalized, and sustained interventions are needed in CBT, as adiposity is only one of many risk factors that
may respond to lifestyle alteration.
There are several limitations to our study. While the WHR and WHtR demonstrated the presence of excess
central adiposity in CBT, it is not clear if this is due to subcutaneous or visceral fat depot expansion. It is also
unclear yet if these adiposity patterns will be sustained as CBT age. In addition, due to the cost and logistics
involved we did not measure other fat depots including hepatic and intermyocellular fat. Larger sample size and
longitudinal studies of the fat depots are needed starting at diagnosis, to elucidate the evolution of the adiposity
patterns in CBT.
As the questionnaires were self-administered, the presence of recall bias is possible. However, this is less likely,
as the data collected were related to recent lifestyle factors, and the clinical data related to the tumor and its treatment were collected from the medical records.

Conclusions

In summary, our study reveals that excess total and central adiposity are present in non-craniopharyngioma population of CBT compared to controls. Adiposity, especially central adiposity, is an important cardiometabolic risk
marker that appears in CBT within few years of their diagnosis. Tumor location and radiotherapy are important
determinants of the noted adipose phenotype in these patients.
There is a need to understand the determinants of adiposity so that new therapies and prevention strategies can
be developed to mitigate premature cardiovascular diseases and type 2 diabetes and improve outcomes in CBT.

Methods

Participants.

The participants in this study were recruited into the Canadian Study of Determinants of
Endometabolic Health in Children (CanDECIDE Study). This is a cohort study based at McMaster Children’s
Hospital, a tertiary pediatric academic center in Hamilton, Ontario, Canada. The study protocol and feasibility
have been published51,52. The data reported are cross-sectional data collected at recruitment into the study.
We consecutively recruited CBT from the neurooncology clinics, and non-cancer controls were recruited
from orthopedic clinics at the hospital and from the community. The orthopedic clinic controls included healthy
children who suffered fractures or sprains and were seen for evaluation. Importantly, all study measures were
performed after the fractures or sprains have healed, and participants had returned to their usual lifestyle before
the injury. The recruitment period lasted from November 2012-March 2016.
We recruited boys and girls, 5 years and older, who were free of infection for 15 days prior to participation
in the study, with no history of autoimmune diseases and not receiving immunosuppressive therapy for 15 days
prior to inclusion. The exclusion criteria included active infection, autoimmune diseases, pregnancy or inability
to provide informed consent.

Consent. The Hamilton Integrated Research Ethics Board approved this study. Consent forms were signed
by parents if the participants were less than 16 years old, or by the participants if they were 16 years or older53.
Children 7–15 years of age also signed an additional assent form. Informed consent was obtained from all participants. The study was conducted in accordance with appropriate clinical practice guidelines and national legal
requirements.
Sociodemographic and clinical data. Data collected during the initial encounter with potential participants included self-reported age and sex, and this was confirmed from the medical records. Additional data
collected from the medical records included age at diagnosis, tumor type, location, details of treatments received,
and associated endocrinopathies and their treatment. Pubertal staging was assessed by pictorial Tanner pubertal
staging in girls (>8 year old) and boys (>9 year old)54.
Height and weight were measured to the nearest one tenth of a centimeter and one tenth of a kilogram using
a stadiometer and an electronic weighing scale (Seca, USA), respectively. Body mass index (BMI) was calculated
as kg/m2. BMI percentile was obtained using the Children’s BMI Tool for Schools55 and BMI z-score were determined from the Centers for Disease Control and Prevention (CDC) growth chart56. Sitting systolic and diastolic
blood pressures were measured twice using the right arm with an automated blood pressure monitor (Welch
Allyn, Inc., USA) and the average values of these two measurements are reported.
The two commonly used methods to measure body fat include Dual-energy X-ray absorptiometry (DXA)
scan and bioelectrical impedance analysis (BIA)57. The latter is less expensive, easier to access and perform than
DXA. In this study, we used BIA to measure %FM to determine total adiposity. This method has been validated
against DXA scans, and the two measures are highly correlated57. While the Tanita body fat monitor (Tanita
Corporation, Illinois, USA) is portable, it cannot be used on those 18 years and older. In this case, the InBody520
body composition analyzer (Biospace Co., Ltd, Korea) was used to measure %FM. High correlations were established between the Tanita body fat monitor and the InBody520 body composition analyzer when tested on 5–17
year old children (r =  0.87; p-value =  0.001).
Waist and hip circumferences were measured to the nearest one tenth of a centimeter, using a spring-loaded
measuring tape (OHAUS Corporation, Canada)58. Central adiposity was determined by calculating the WHR
and WHtR21.
Diet.

Dietary intake was assessed as we previously reported52. Briefly, we used items from the Youth and
Adolescent Food Frequency Questionnaire52,59,60. This is a questionnaire developed in a US pediatric cohort,
and includes questions about food intake based on average portion sizes of different dietary constituents. The
number of servings per day was calculated from the questionnaire by multiplying the frequency of consumption
by portion size.
SCIENTIfIC REporTS | 7:45078 | DOI: 10.1038/srep45078

6

www.nature.com/scientificreports/
Principal component analysis was used to analyze the dietary patterns in participants. This analysis revealed
four dietary patterns including prudent, western, high-protein and refined carbohydrate diets (Table 4). The
prudent diet included high intake of fruits and vegetables. The western diet included high intake of fried foods,
desserts, baked goods, and refined foods (e.g., chips, snacks, candies). The high-protein diet included high intake
of meat and eggs. The refined carbohydrate diet included high intake of white bread and low intake of dark (whole
grain) bread.

Physical activity.

Physical activity was measured using the Habitual Activity Estimation Scale (HAES)61.
The participants were asked to indicate their overall physical activity level as very inactive, inactive, somewhat
inactive, somewhat active, active, or very active. This data were used to report physical activity levels. The levels
were dichotomized into active and inactive for statistical analyses.

Sleep.

Sleep duration (hours/day) was calculated from the difference between the self-reported time the participant went to bed and woke up the next morning. Sleep duration calculated with this method has been shown
to correlate well with objective sleep quantification methods62.

Screen time. Total screen time (hours/day) was calculated from the sum of self-reported time spent watching
television, using cell phone, computer, computer games, and tablets.
Statistical analysis.

All analyses were performed with SPSS version 20 software63. Kolmogorov-Smirnov
test was used to test for normality, and variables with non-normal distribution were log-transformed. Age
log-transformation revealed no outliers.
We used variance inflation factor to test for collinearity of variables, and found none that were collinear.
Multiple imputations were used to handle missing data.
Continuous variables are reported as mean ± SD, and categorical variables are reported as counts (%).
Chi-square tests and independent sample t-tests were used to compare brain tumor survivors and controls for
categorical and continuous variables, respectively. We used Spearman’s test to assess the correlation of adiposity
measures with BMI and with each other in this study.
To assess the association of adiposity with brain tumor status, we used binary logistic regression. The
dependent variable (event) was the cancer case status, with 56 events included in the analysis and 106 controls
(non-events). Age, sex, %FM, WHR, and WHtR were included as the predictor variables in the analysis. We rescaled the WHR and WHtR coefficients by multiplying the log-transformed data by 1064,65. Logistic regression was
conducted based on the assumption that ten events per predictor variable are needed for the analysis. As there
are five predictor variables included in the analysis, our study is sufficiently powered to answer the main study
question.
To explore the determinants of the adiposity patterns in CBT and controls, we performed exploratory subgroup analyses of the cancer cases and controls separately with multivariate linear regression analysis. The
dependent variables included %FM, WHR, and WHtR.
The predictor variables of interest in CBT included age, sex, puberty, brain tumor histopathology, tumor location, and treatments including surgery, radiotherapy, chemotherapy, and steroids. In addition, we included lifestyle factors encompassing diet, physical activity, screen time, and sleep duration in the analysis. For controls, we
included age, sex, puberty, diet, physical activity, screen time, and sleep duration in the analysis. The sample size
of 56 events and 106 non-events provide adequate power for this analysis, as two events per variable are required
in linear regression analyses to address the question of adiposity determinants in CBT and controls66. To analyze
the dietary patterns in participants, we used principal component analysis. Twenty-two food items were included
in the factor analysis. The number of dietary patterns retained was determined by visual inspection of scree plots
in conjunction with eigenvalues (>1.0) and principal component interpretability. The factors were orthogonally
transformed by using the varimax rotation to ensure the independence of factors in the structure. Dietary patterns
were characterized based on dietary items with their factor loadings ≥|0.30|. The PCA scores for each pattern
obtained for each individual represented how closely their food choices reflected one of the empirically-derived
dietary patterns, with higher scores reflecting a greater degree of adherence to that dietary pattern67.
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